Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Woodstock Sterile Solutions Appoints CCO | Contract Pharma
Breaking News

Woodstock Sterile Solutions Appoints CCO

Bill Hartzel will report to Woodstock CEO Paul Josephs.

Woodstock Sterile Solutions, a blow-fill-seal (BFS) contract development and manufacturing organization (CDMO), has appointed Bill Hartzel as the company’s first chief commercial officer (CCO). Hartzel assumes the role immediately and will report to Woodstock CEO Paul Josephs.
 
“We are pleased to welcome a dynamic, customer-focused leader like Bill Hartzel to the Woodstock executive team,” said Josephs. “Bill has had an impressive career in the BFS industry and we look forward to him bringing the exceptional business and technical acumen he has demonstrated throughout his career to our leadership team to help us drive sustainable growth for the organization.”
 
In his role as CCO, Hartzel is responsible for the commercial activities and strategy for Woodstock Sterile Solutions, overseeing its sales, marketing and commercial operations teams, as well as contracting for the organization.
 
Experience
 
Hartzel has worked for Woodstock Sterile Solutions and the BFS business of its predecessor, Catalent, for more than a decade, serving in a variety of commercial roles with increasing responsibility. He joined Catalent in 2012 as a product manager in Medication Delivery Solutions, then moved to Woodstock, IL as director of strategic execution before being promoted to the regional director of commercial operations. He next rose to the position of global vice president of business development for Analytical, Respiratory, and Ophthalmics.
 
“I am very excited about the opportunities and the potential for growth for Woodstock Sterile Solutions in the pharmaceutical and healthcare industry,” Hartzel commented. “BFS is an untapped technology and it is primed for growth and expansion—not just in the respiratory and ophthalmic space—but as a sterile delivery platform, where it can help to mitigate the risks involved with sterile manufacturing. The Woodstock business is uniquely positioned to support complex formulations seamlessly from development through commercial production. I look forward to helping Woodstock Sterile Solutions reach its full potential in this market.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters